| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. …
Over the last 12 months, insiders at Cumberland Pharmaceuticals Inc. have bought $0 and sold $0 worth of Cumberland Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Cumberland Pharmaceuticals Inc. have bought $42,157 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 13 shares for transaction amount of $45 was made by KAZIMI A J (Chairman and CEO) on 2025‑08‑29.
| 2025-08-29 | KAZIMI A J | Chairman and CEO | 13 <0.0001% | $3.45 | $45 | +11.25% | ||
| 2025-08-29 | Krogulski Kenneth | director | 68 0.0004% | $3.45 | $235 | +11.25% | ||
| 2025-08-29 | Jones James | director | 13 <0.0001% | $3.45 | $45 | +11.25% | ||
| 2025-08-29 | Young Caroline | director | 6 <0.0001% | $3.45 | $21 | +11.25% | ||
| 2025-08-28 | KAZIMI A J | Chairman and CEO | 13 <0.0001% | $3.47 | $45 | +11.90% | ||
| 2025-08-28 | Krogulski Kenneth | director | 68 0.0005% | $3.47 | $236 | +11.90% | ||
| 2025-08-28 | Jones James | director | 13 <0.0001% | $3.47 | $45 | +11.90% | ||
| 2025-08-28 | Young Caroline | director | 6 <0.0001% | $3.47 | $21 | +11.90% | ||
| 2025-08-27 | KAZIMI A J | Chairman and CEO | 13 <0.0001% | $3.44 | $45 | +13.64% | ||
| 2025-08-27 | Krogulski Kenneth | director | 68 0.0005% | $3.44 | $234 | +13.64% | ||
| 2025-08-27 | Jones James | director | 13 <0.0001% | $3.44 | $45 | +13.64% | ||
| 2025-08-27 | Young Caroline | director | 6 <0.0001% | $3.44 | $21 | +13.64% | ||
| 2025-08-26 | KAZIMI A J | Chairman and CEO | 13 <0.0001% | $3.39 | $44 | +13.26% | ||
| 2025-08-26 | Krogulski Kenneth | director | 68 0.0005% | $3.39 | $231 | +13.26% | ||
| 2025-08-26 | Jones James | director | 13 <0.0001% | $3.39 | $44 | +13.26% | ||
| 2025-08-26 | Young Caroline | director | 6 <0.0001% | $3.39 | $20 | +13.26% | ||
| 2025-08-25 | KAZIMI A J | Chairman and CEO | 13 <0.0001% | $3.32 | $43 | +18.18% | ||
| 2025-08-25 | Krogulski Kenneth | director | 68 0.0005% | $3.32 | $226 | +18.18% | ||
| 2025-08-25 | Jones James | director | 13 <0.0001% | $3.32 | $43 | +18.18% | ||
| 2025-08-25 | Young Caroline | director | 6 <0.0001% | $3.32 | $20 | +18.18% |
| KAZIMI A J | Chairman and CEO | 5700030 38.0431% | $24.57M | 471 | 1 | <0.0001% |
| Edwards Robert | director | 400970 2.6761% | $1.73M | 1 | 1 | <0.0001% |
| Krogulski Kenneth | director | 289717 1.9336% | $1.25M | 487 | 0 | <0.0001% |
| Cearnal Martin E | Sr VP/Chief Commercial Officer | 178473 1.1912% | $769,218.63 | 172 | 0 | <0.0001% |
| JACOBS JOEY A | director | 88415 0.5901% | $381,068.65 | 38 | 0 | <0.0001% |
| Galante Joseph C | director | 57356 0.3828% | $247,204.36 | 304 | 0 | <0.0001% |
| Jones James | director | 43938 0.2933% | $189,372.78 | 366 | 0 | <0.0001% |
| Young Caroline | director | 32942 0.2199% | $141,980.02 | 477 | 0 | <0.0001% |
| Pavliv Leo | Sr. Vice President, Operations | 26445 0.1765% | $113,977.95 | 1 | 1 | <0.0001% |
| Bonner Michael | Chief Financial Officer | 18454 0.1232% | $79,536.74 | 9 | 0 | <0.0001% |
| Hamm John M. | Chief Financial Officer | 6800 0.0454% | $29,308.00 | 1 | 0 | +6.39% |
Cumberland Pharmaceuticals Inc. (CPIX) | $2,101,005 | 2135 | -11.51% | $64.58M |
$131,310,609 | 62 | 26.99% | $107.44M | |
$30,221,759 | 51 | 0.50% | $20.6M | |
$2,767,882 | 51 | 8.70% | $24.78M | |
$33,884,330 | 45 | 12.56% | $223.45M |
| Increased Positions | 8 | +18.18% | 436,569 | +12.82% |
| Decreased Positions | 18 | -40.91% | 885,132 | -25.99% |
| New Positions | 4 | New | 415,462 | New |
| Sold Out Positions | 7 | Sold Out | 618,703 | Sold Out |
| Total Postitions | 34 | -22.73% | 3M | -13.17% |
| Millennium Management Llc | $2,383.00 | 3.99% | 598,634 | -177,342 | -22.85% | 2025-09-30 |
| Ikarian Capital, Llc | $2,213.00 | 3.71% | 555,932 | -40,000 | -6.71% | 2025-09-30 |
| Renaissance Technologies Llc | $2,052.00 | 3.44% | 515,465 | +20,502 | +4.14% | 2025-09-30 |
| Vanguard Group Inc | $1,639.00 | 2.75% | 411,786 | 0 | 0% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $1,118.00 | 1.87% | 280,869 | +27,980 | +11.06% | 2025-09-30 |
| J. Goldman & Co Lp | $828.00 | 1.39% | 208,143 | -12,564 | -5.69% | 2025-09-30 |
| Bridgeway Capital Management, Llc | $750.00 | 1.26% | 188,355 | 0 | 0% | 2025-09-30 |
| Boothbay Fund Management, Llc | $669.00 | 1.12% | 168,132 | -12,097 | -6.71% | 2025-09-30 |
| Geode Capital Management, Llc | $404.00 | 0.68% | 101,621 | +1,384 | +1.38% | 2025-09-30 |
| Bank Of New York Mellon Corp | $289.00 | 0.48% | 72,513 | 0 | 0% | 2025-09-30 |